Last updated: October 18, 2026
BromSite is Sun Pharmaceutical Industries’ branded bromfenac ophthalmic solution for postoperative inflammation and ocular pain following cataract surgery. Its commercial position depends on three factors: cataract-procedure volume, reimbursement for branded ophthalmic products, and differentiation from lower-cost generic NSAID eye drops. BromSite has a clinical-use advantage from twice-daily dosing and its DuraSite delivery vehicle, but it competes in a mature market with generic bromfenac, ketorolac, and nepafenac products.
Sun Pharma does not separately disclose BromSite revenue, operating profit, prescription volume, or product-level margins. The product is reported within broader U.S. specialty and ophthalmic pharmaceutical businesses. Its financial contribution is therefore best assessed through market position, prescription demand, pricing, and the durability of its formulation and regulatory barriers rather than through a standalone public income statement.
What is BromSite and how is it used?
BromSite contains bromfenac ophthalmic solution 0.075%, a topical nonsteroidal anti-inflammatory drug, or NSAID. The product is indicated for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
| Attribute |
BromSite |
| Active ingredient |
Bromfenac |
| Strength |
0.075% ophthalmic solution |
| Dosage form |
Topical eye drop |
| FDA approval |
2016 |
| Developer and marketer |
InSite Vision initially; Sun Pharma after acquisition |
| Main indication |
Postoperative inflammation and ocular pain after cataract surgery |
| Typical administration |
Twice daily beginning on the day of cataract surgery and continuing for 14 days |
| Delivery technology |
DuraSite ocular delivery vehicle |
| Product type |
Branded small-molecule ophthalmic drug |
BromSite’s main practical distinction is reduced dosing frequency. Many competing postoperative NSAID products require once-daily or four-times-daily administration depending on the product and label. BromSite’s twice-daily regimen provides a commercial selling point for surgeons and patients, although lower-cost generic alternatives can limit the value of that differentiation.
How large is the BromSite market?
The addressable market is tied primarily to cataract surgery rather than to chronic ophthalmic disease. Cataract surgery is one of the most frequently performed procedures in the United States, creating a large recurring prescription base. The market includes postoperative corticosteroids, NSAIDs, antibiotics, and combination products.
BromSite competes within the postoperative NSAID segment against:
- Generic bromfenac ophthalmic products, usually based on the older 0.09% formulation.
- Prolensa, a branded bromfenac 0.07% product marketed by Bausch + Lomb.
- Generic ketorolac ophthalmic products.
- Nevanac and generic nepafenac.
- Combination postoperative regimens that pair an antibiotic with a steroid or NSAID.
The market is structurally attractive because cataract surgery volumes are recurring and demographic aging supports long-term demand. It is commercially difficult because the product is used for a short treatment course, physician prescribing is concentrated among ophthalmologists, and payers generally place pressure on branded topical products.
What drives BromSite demand?
BromSite demand is driven by procedure volume, surgeon preference, formulary access, and perceived adherence benefits.
Cataract surgery volume
The largest demand driver is the number of cataract procedures. An aging population, increased diagnosis of cataracts, and continued outpatient migration support procedure growth. Changes in surgical technique also influence prescription patterns. Surgeons may use branded NSAIDs when they believe a formulation improves comfort, adherence, or postoperative control.
Twice-daily dosing
BromSite’s twice-daily administration can reduce the burden associated with postoperative eye-drop regimens. The benefit is commercially relevant because cataract patients often receive multiple drops. The advantage is weaker when physicians prescribe lower-cost generic alternatives or use simplified combination regimens.
DuraSite formulation
DuraSite is a water-soluble polymer delivery technology designed to increase ocular residence time. In BromSite, the technology supports the formulation’s dosing profile and provides a potential barrier against straightforward substitution with generic bromfenac products.
The formulation does not eliminate generic risk. A generic applicant can challenge patents, develop an alternative formulation, or receive approval for a product that does not copy every protected feature.
Surgical center purchasing
Cataract surgery is increasingly performed in ambulatory surgery centers and organized ophthalmology networks. Institutional purchasing can favor products with predictable reimbursement, bundled pricing, or supply reliability. This creates scale advantages for manufacturers but can also increase price pressure.
How does BromSite compare with competing ophthalmic NSAIDs?
| Product |
Ingredient |
Brand owner or major marketer |
Main commercial advantage |
Primary risk |
| BromSite |
Bromfenac 0.075% |
Sun Pharma |
Twice-daily regimen and DuraSite formulation |
Generic and branded bromfenac competition |
| Prolensa |
Bromfenac 0.07% |
Bausch + Lomb |
Established branded bromfenac position |
Direct class competition and payer pressure |
| Generic bromfenac |
Bromfenac, commonly 0.09% |
Multiple generic manufacturers |
Low price |
Less formulation differentiation |
| Nevanac |
Nepafenac |
Novartis historically; generic competition |
Established postoperative NSAID use |
Generic substitution |
| Ketorolac ophthalmic |
Ketorolac |
Multiple manufacturers |
Low cost and broad availability |
Frequent dosing and commoditization |
BromSite’s strongest competitive position is against products that require more frequent administration. Its weakest position is against generic drugs that are clinically familiar and materially cheaper.
What is BromSite’s FDA regulatory status?
BromSite is an FDA-approved prescription ophthalmic product. Its regulatory status is that of a branded small-molecule drug, not a biologic. Biosimilar competition is therefore not relevant.
The relevant FDA pathway for a generic competitor is an abbreviated new drug application, or ANDA. Generic applicants can seek approval by demonstrating pharmaceutical equivalence and bioequivalence or by satisfying the applicable FDA requirements for ophthalmic products. A branded formulation may still face substitution risk even when its vehicle, concentration, or dosing instructions differ from those of the reference product.
FDA approval does not guarantee continued commercial exclusivity. Market protection depends on patents, regulatory exclusivity, prescribing behavior, and payer coverage.
What patents protect BromSite?
BromSite’s protection is expected to center on formulation, delivery technology, composition, and methods of treating postoperative ocular inflammation and pain. The relevant patent estate is associated with bromfenac ophthalmic formulations and the DuraSite platform developed by InSite Vision.
Public company disclosures do not provide a standalone BromSite patent schedule with product-level expiration dates and claim-by-claim scope. Sun Pharma reports intellectual-property risks at a broader business level rather than publishing a complete BromSite lifecycle table.
| Protection category |
Relevance to BromSite |
| Active ingredient patent |
Limited value because bromfenac is an established molecule |
| Composition patent |
May protect concentration, excipients, or specific ophthalmic combinations |
| Formulation patent |
Potentially protects DuraSite-based delivery characteristics |
| Method-of-use patent |
May cover treatment of postoperative inflammation or pain |
| Manufacturing patent |
May protect production or sterilization processes |
| Regulatory exclusivity |
Short-term approval-related protection, if applicable |
| Trademark protection |
Protects the BromSite brand, not the active ingredient |
The key commercial issue is whether a generic applicant can enter with a formulation that avoids enforceable claims. A patent covering the DuraSite vehicle may be valuable if it prevents direct substitution, but it may not block all bromfenac products.
When does BromSite lose exclusivity?
A definitive public loss-of-exclusivity date cannot be assigned from the product’s approval date alone. The effective date depends on the expiration of listed patents, pediatric exclusivity, regulatory exclusivity, patent-term adjustments, and any Paragraph IV litigation or settlement.
BromSite was approved in 2016, so any five-year new-chemical-entity exclusivity associated with the active ingredient would not remain a current barrier. Bromfenac itself was previously approved in other ophthalmic products, making product-specific formulation and method patents more important than new-molecule exclusivity.
Generic entry could occur before the latest patent expiration if:
- A generic applicant files a Paragraph IV certification.
- The patent holder does not sue within the statutory period.
- Litigation ends in a judgment of invalidity or non-infringement.
- The parties settle on an authorized or licensed entry date.
- FDA approves a product that does not infringe the relevant claims.
Are there Paragraph IV challenges to BromSite?
A Paragraph IV certification is a generic applicant’s assertion that a listed patent is invalid, unenforceable, or not infringed. It can trigger patent litigation and, in many cases, a 30-month stay of FDA approval.
No broadly reported, product-defining Paragraph IV litigation outcome for BromSite is identified in Sun Pharma’s general public financial reporting through the latest available company disclosures. That does not establish that no ANDA challenge has been filed. Product-level litigation can be reported under a patent owner, subsidiary, formulation developer, or generic applicant rather than under the brand name.
The practical exposure is still significant because BromSite’s market is small-molecule and short-course. Even a single approved generic can rapidly reset net pricing.
What is the financial trajectory for BromSite?
Sun Pharma does not report BromSite as a separate revenue line. The product is included in broader U.S. specialty, ophthalmology, or generic and branded portfolio reporting, depending on the company’s reporting structure.
The likely financial trajectory has four phases:
| Phase |
Commercial pattern |
| Launch and adoption |
Physician education, formulary placement, and conversion from competing postoperative NSAIDs |
| Expansion |
Growth from cataract procedure volume and increased surgeon familiarity |
| Maturity |
Stable prescription demand with pressure from competing branded and generic products |
| Post-generic risk |
Rapid net-price erosion, lower market share, and possible shift to niche or contract pricing |
BromSite’s revenue quality is likely stronger than a fully commoditized generic because the product has a branded formulation and dosing rationale. Its revenue ceiling is limited by the short treatment duration, restricted indication, and availability of alternative NSAIDs.
Sun Pharma’s broader financial trajectory is more important than BromSite’s standalone economics. The company has continued to emphasize specialty products, complex generics, and differentiated formulations. BromSite fits that strategy because it uses a branded delivery platform rather than competing solely on active ingredient cost.
What generic launch risks exist for BromSite?
The principal generic-entry risks are:
- Approval of a generic bromfenac product with a lower acquisition cost.
- Payer-mandated substitution or step therapy.
- Reduced physician sensitivity to dosing differences.
- Loss of preferred formulary placement.
- Contracting pressure from ambulatory surgery centers.
- Patent invalidity or non-infringement findings.
- Settlement agreements that permit an earlier generic launch.
- A competing branded product offering deeper discounts.
The economic impact would likely be concentrated in net price and prescription share rather than in total procedure volume. Cataract surgeries would continue, but the value captured by BromSite could decline sharply.
What patent litigation affects BromSite?
Public reporting has not identified a major BromSite litigation event that materially changed the product’s commercial trajectory through the latest available disclosures. Sun Pharma’s annual reports discuss litigation and intellectual-property matters at portfolio level, which limits product-specific conclusions.
A future dispute would most likely involve:
- Infringement of formulation claims.
- Validity of DuraSite-related patents.
- Patent-term calculations.
- ANDA approval timing.
- Settlement terms governing generic entry.
- Whether a generic formulation is sufficiently different to avoid infringement.
How strong is the BromSite patent estate?
BromSite’s patent estate is moderately differentiated but not comparable to the estate of a novel systemic drug. The active ingredient is old, and the commercial protection depends on formulation and delivery claims. Those claims can support branded pricing, but they are often narrower and more vulnerable to design-around strategies than composition-of-matter patents.
The strongest barriers are likely to be:
- Formulation claims tied to the DuraSite vehicle.
- Claims covering a specific bromfenac concentration and excipient combination.
- Method claims linked to postoperative dosing.
- Manufacturing controls that are difficult to replicate economically.
The weakest barriers are likely to be the underlying bromfenac molecule and broad treatment claims that overlap with established ophthalmic NSAID use.
What licensing deals affected BromSite?
BromSite originated with InSite Vision, whose ophthalmic drug-delivery assets were acquired by Sun Pharma in 2015. The transaction gave Sun Pharma access to BromSite, DuraSite technology, and related ophthalmic development capabilities.
The acquisition is more commercially important than a conventional product license because it transferred the underlying platform and product rights to Sun Pharma. Public disclosures do not establish a separate, ongoing royalty stream for BromSite comparable to a third-party licensing agreement.
What is the BromSite generic launch scenario?
The most likely entry scenarios are:
| Scenario |
Commercial effect |
| No approved generic for an extended period |
Continued branded pricing, but ongoing payer pressure |
| One approved generic |
Significant price concessions and selective formulary loss |
| Multiple generics |
Rapid commoditization and substantial revenue erosion |
| Authorized generic or settlement entry |
Controlled erosion before full generic competition |
| Non-infringing formulation entry |
Patent protection narrowed without eliminating substitution |
BromSite’s short treatment cycle means pharmacies and patients can switch quickly after generic approval. The company may respond with rebates, patient support, surgeon targeting, or portfolio bundling with other ophthalmic products.
How does BromSite compare with Prolensa?
BromSite and Prolensa compete directly in branded bromfenac ophthalmic therapy. BromSite uses a 0.075% concentration and DuraSite delivery technology, while Prolensa uses a 0.07% formulation. Both products target postoperative inflammation and pain following cataract surgery.
The competitive outcome depends less on nominal concentration than on:
- Dosing frequency.
- Physician familiarity.
- Formulary status.
- Contract pricing.
- Generic substitution rules.
- Perceived tolerability and adherence.
- Sales-force reach into ophthalmology practices.
Neither product has the protection profile of a new molecular entity. Both face long-term pressure from generic NSAIDs and payer efforts to reduce branded ophthalmic spending.
Key Takeaways
- BromSite is a branded bromfenac ophthalmic product marketed by Sun Pharma for postoperative cataract-surgery inflammation and pain.
- Its principal differentiation is twice-daily dosing and the DuraSite delivery platform.
- Sun Pharma does not separately disclose BromSite revenue or profitability.
- The product’s market grows with cataract surgery volume but faces persistent generic and branded competition.
- Biosimilar risk is not relevant because BromSite is a small-molecule ophthalmic drug.
- The patent estate is likely centered on formulation, delivery technology, and method-of-use claims rather than the bromfenac molecule.
- Product-level public data do not establish a definitive BromSite patent-expiration date.
- A single approved generic could create substantial net-price and market-share pressure.
- BromSite’s financial value is best assessed as part of Sun Pharma’s broader U.S. specialty ophthalmology portfolio.
FAQs About BromSite Market and Exclusivity
Does BromSite have a biosimilar competitor?
No. BromSite is a small-molecule drug, so competitors would enter through the generic-drug pathway rather than through the biosimilar pathway.
Is BromSite stronger than generic bromfenac?
BromSite differs mainly in formulation, concentration, delivery technology, and labeled dosing. Clinical and commercial superiority cannot be determined from the active ingredient alone.
Who owns the BromSite patents?
Sun Pharma controls the commercial rights acquired through its purchase of InSite Vision and its ophthalmic delivery assets. Specific patent ownership can vary by patent family and assignment history.
Can pharmacies automatically substitute generic bromfenac for BromSite?
Substitution depends on FDA therapeutic-equivalence ratings, state pharmacy law, payer policy, and the specific generic product. A generic with a different formulation or rating may not be automatically substitutable in every setting.
What would most reduce BromSite revenue?
The largest direct threat would be FDA approval of one or more generic products that obtain broad payer coverage and are accepted by ophthalmologists as clinically interchangeable.
References
- U.S. Food and Drug Administration. (2016). BromSite (bromfenac ophthalmic solution) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Sun Pharmaceutical Industries Ltd. (2024). Annual report 2023-2024.
- Sun Pharmaceutical Industries Ltd. (2015). Sun Pharma completes acquisition of InSite Vision.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
